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Summary A mutation at codon 974 of the dihydropyrimidine dehydrogenase (DPD) gene was previously described in a cancer patient with
undetectable DPD enzyme activity who experienced severe toxicity when treated with 5-fluorouracil. We have studied the frequency of this
mutation in 29 Scottish subjects with low DPD enzyme activity and in 274 American subjects. We detected no mutations in the 606 alleles
studied and conclude that mutations at codon 974 are a rare event.
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The first and rate-limiting step in the catabolism of the pyrim-
idines uracil and thymine is carried out by the enzyme dihydropy-
rimidine dehydrogenase (DPD: EC 1.3.1.2). DPD enzyme activity
has been detected in a number of human tissues, with the highest
levels in the liver and lymphocytes (Naguib et al 1985). Population
studies have shown that enzyme activity has a unimodel distribu-
tion over a 7- to 14-fold range, with some individuals having very
low or even undetectable levels (Lu et al 1993; Etienne et al 1994;
McMurrough and McLeod 1996). Low DPD activity is clinically
important as such individuals can exhibit severe toxicity when
treated with the anti-cancer agent 5-fluorouracil (5-FU) (Harris et
al 1991; Houyau et al 1993). In addition, total DPD deficiency is
associated with the congenital syndrome thymine uraciluria
(Meinsma et al 1995). Population studies of DPD activity have
suggested that the frequency of heterozygous and homozygous
deficiency is 3% and 0.1% respectively (Milano and Etienne
1994). Two molecular alterations in the DPYD gene have been
reported to date in patients with low enzyme activity. The deletion
of a 165-bp exon has been demonstrated in a child with thymine
uraciluria and in an adult who experienced near-fatal toxicity after
receiving 5-FU therapy (Meinsma et al 1995; Wei et al 1996). A
point mutation at codon 974 (aspartic acid to valine) has been
identified in a patient who experienced severe 5-FU-related toxi-
city (Harris et al 1991; Albin et al 1995). The aspartic acid residue
at codon 974 is not within the putative catalytic sites ofthe protein
(Gonzalez and Fernandez-Salguero 1995) and the amino acid is
conserved in the human, pig and cow sequences (GenBank/EMBL
Accession numbers U09178, U09179 and U20981). The popula-
tion frequency ofthese mutations is not known.
A polymerase chain reaction-restriction fragment length poly-
morphism (PCR-RFLP) assay was used to study the prevalence of
point mutations at codon 974 in two population cohorts. Initial
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studies were conducted in 29 Scottish blood donors with low DPD
activity (19.1-69.3 pmol min-'mg-' protein), as measured using a
high-performance liquid chromatography (HPLC)-based method
for detecting radioactive metabolites (McMurrough and McLeod,
1996). This represented the lowest 10% of a larger population
study. DNA from 274 American black and white blood donors
(Memphis, TN; McLeod et al, 1994) was also analysed, as these
samples were collected from a region ofgeographical proximity to
the originally reported case (Birmingham, AL; Harris et al, 1991;
Albin et al, 1995). DPD catalytic activity was not available for the
American subjects.
MATERIALS AND METHODS
PCR-RFLP analysis
The presence of a mutation at codon 974 was screened for using
PCR to amplify a 238-bp fragment from genomic peripheral
blood lymphocyte DNA using primers AspF2 (5'-CAATACCCTC-
TATGTCTGTTTGC-3') and AspR2 (5'-GTAGGTGACAT-
GAAAGATCACAG-3'). Reactions (50,l) were carried out in 50
mM potassium chloride 10 mM Tris-HCl, pH 9.0, 0.1% Triton
X-100, 2.25 mM magnesium chloride, 0.8 mM dNTPs, 100 ng
of each primer, 2.5 units Taq polymerase (Promega) and 100 ng
genomic DNA. A control reaction with no DNA was also included.
Amplification was carried out using 30 cycles of 95°C for 30 s,
58°C for 30 s and 72°C for 30 s. The presence of a mutation at
codon 974 was detected by digesting 10 itl of each PCR sample
with Mbol (in 10 mm Tris-HCl, pH 7.8, 10 mm magnesium chlo-
ride, 1 mm dithiothreitol) for 2 h at 37°C. The presence of a point
mutation at codon 974 destroys an MboI site (GATC to GTTC).
There was also an MboI site present in primer AspR2 (underlined
and created by incorporating a single mismatched base at position
17 of the primer). The presence of this additional site provided a
control for MboI activity in all digests. Digestion ofthe PCR frag-
ment with MboI resulted in the production of three bands in wild-
type samples (183 bp, 36 bp and 19 bp) and two bands in mutant
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Figure 1 Analysis of mutations at codon 974 of the DPYD gene. Eight different samples (C) were digested with Mbol and analysed on a 2.5% agarose gel. No
mutations were present. L, 1-kb ladder (Gibco BRL); C, Mbol-digested samples. Controls: W (wild-type, 183 bp), H (heterozygous mutant and wild-type, 219 bp
and 183 bp) and M (mutant, 219 bp) were also digested with Mbol. U, uncut 238-bp fragment
samples (219 bp and 19 bp). In heterozygote samples, four bands
were present (219 bp, 183 bp, 36 bp and 19 bp). The digested
products were analysed on a 2.5% agarose gel, which allowed the
visualization of the 219-bp and 183-bp bands, which indicated
the presence or absence of a mutation at codon 974 (Figure 1).
An additional control was created using primer AspF3 (5'-CAAT-
ACCCTCTATGTCTGTTTGCAGGCTATACAGTTTGTTCCAG-
3'), which incorporates a mutation at codon 974 that destroys the
MboI site (underlined). Digestion of this product with MboI
resulted in the formation of 219-bp and 19-bp fragments. A simu-
lated heterozygote was created by mixing equal amounts of wild-
type (Asp F2 and Asp R2) and mutant (Asp F3 and Asp R2) PCR
products, heating the samples to 95°C and then digesting with
MboI, as described above. These controls were run on each gel.
RESULTS AND DISCUSSION
No mutations were detected in the 303 samples (606 alleles)
analysed, suggesting that the frequency of this mutation is low
(< 0.2% of alleles). The lack of mutations in the 29 Scottish
subjects with the lowest enzyme activity suggests that this muta-
tion is not frequently associated with reduced DPD activity. The
lower threshold of DPD activity identifying patients at risk of 5-
FU toxicity is unclear, but has been suggested to be 100 pmol
min-'mg-' protein, which is higher than the activity observed in the
Scottish subjects studied (Etienne et al, 1994). In addition, a
number ofpatients with 5-FU-related toxicity have been described
with DPD activity levels within the range of those studied here
(Houyau et al, 1993; Takimoto et al, 1996). However, it is possible
that the mutation is only found in individuals with very low (<19.1
pmol min-'mg-' protein) or no detectable DPD activity, as
described in the original proband for this mutation (Harris et al,
1991). The absence of mutations in the 274 American subjects
studied further suggests that these mutations are rare, even within
a population of close geographical proximity to the originally
described case.
We conclude that mutations at codon 974 are rare and are
present at a lower frequency than that estimated for cases ofpartial
or complete DPD deficiency (Milano and Etienne, 1994). This
would indicate that other factors, including additional mutations,
are also responsible for DPD deficiency.
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